Caitlin Owens December 3, 2019
The
Trump administration may loosen intellectual property protections for some
prescription drugs in order to win Democratic support for its new trade deal
with Mexico and Canada, the Wall Street Journal
reports.
The big
picture: The protections are a big win for U.S. drug companies, as they
would extend the length of time that biologics can reap the benefits of
monopoly pricing in those two other countries.
Details: The
original version of the new trade pact gave biologics 10 years of market
exclusivity, but Democrats want this time period to be reduced.
- Right
now, biologics have 12 years of market exclusivity in the U.S. They have
only eight in Canada and five in Mexico, per The Globe and Mail.
- Generic
drugmakers argue that 10 years may be too long once manufacturing biosimilars
becomes more efficient.
No comments:
Post a Comment